ΔINK4 T2D risk region hiPSC
HMGUi001-A-5
General
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
| Family history | no |
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA5696688 |
Ethics
Also have a look at the ethics information for the parental line
HMGUi001-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | The targeting vector was generated at IDR, and contained the PU6-(BbsI) sgRNA_CAG-Cas9-GFP-bpA plasmid, Addgene ID86985. |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | Yes |
| Constraints for use or distribution | According to donor consent the line must not be used for commercial purposes. For research purposes project specific review by an Ethics Committee is oblgatory. |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
HMGUi001-A.
|
|
| Passage number reprogrammed | 32 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | HMGUi001-A-1 was targeted with PU6-(BbsI) sgRNA_CAG-Cas9-GFP-bpA plasmid, Addgene ID8698,5 to make a large deletion at the INK4 locus. This vector expresses Cas9 enzyme and sgRNAs. |
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | FACS sorting of GFP expressing cells, genomic DNA exctraction from GFP+ single cell clones, screening for the 8kb deletion by conventional PCR with FA-RB and FC-RC primer pairs, identification of wild type and biallelic clones for the large deletion by a 1910 bp wild type-specific PCR product and a 750 bp deletion-specific PCR product, confirmation of the precise deletion of the target region by Sanger sequencing of the PCR products |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method | EDTA |
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: StemMACS iPS-Brew XF medium
Main protein source: xeno-fee Serum concentration: 0 % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SOX2 |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
StemMACS Trilineage Differentiation plus immunostaining
Differentiation Potency
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46, XX
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.